Corvus Pharmaceuticals, Inc. (CRVS) vs Kura Oncology, Inc. (KURA)
A side-by-side comparison of Corvus Pharmaceuticals, Inc. and Kura Oncology, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
CRVS
Corvus Pharmaceuticals, Inc.
$10.35HealthcareDelayed quote: Oct 6, 2026, 10:50 AM EDT
KURA
Kura Oncology, Inc.
$10.48HealthcareDelayed quote: Oct 6, 2026, 10:50 AM EDT
Total return — CRVS vs KURA
growth of $100 · dividends reinvested · last 10yCRVS -34.5% (-4.1%/yr)KURA +85.0% (+6.3%/yr)KURA compounded faster over this window
CRVS KURA
CRVS vs KURA: by the numbers
- •KURA is the larger company ($930M vs $871M market cap).
- •Both run net losses; CRVS's is the smaller (0.00% vs -384.30% net margin).
Metrics side by side
Valuation
| Metric | CRVS | KURA |
|---|---|---|
| P/S ratio | N/A | 12.05 |
| P/B ratio | 3.86 | 19.21 |
Profitability
| Metric | CRVS | KURA |
|---|---|---|
| Gross margin | 0.00% | 94.73% |
| Operating margin | 0.00% | -449.94% |
| Net margin | 0.00% | -384.30% |
| ROE | -24.02% | -612.78% |
| ROIC | -25.25% | -67.13% |
Growth (annualized)
| Metric | CRVS | KURA |
|---|---|---|
| Total return CAGR (5Y) | 17.88% | -10.73% |
Frequently asked
- How have CRVS and KURA total returns compared?
- Over the past 10 years, CRVS delivered -4.26% and KURA delivered 5.98% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.